Protagenic Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals

Chief operating officer to present key advances at peptide therapeutics summit new york, ny / accesswire / april 17, 2024 / protagenic therapeutics, inc. (nasdaq:ptix), a pioneer in biopharmaceutical research, announced today that dr. andrew slee, chief operating officer, will present a talk on pt00114, the company's promising new drug candidate, at the peptide based therapeutic summit in boston. titled "novel blood-brain barrier penetrating peptide: opening new doors in neuro-psychiatric treatment," dr. slee's talk will focus on the groundbreaking structure of pt00114, designed to efficiently cross the blood-brain barrier and unlock new potential in treating serious neuro-psychiatric conditions.

Transitioned from pre-clinical to clinical stage company in fy 2023 phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with treatment-resistant depression, ptsd or generalized anxiety disorder, progressing through phase 1 portion plans to enroll final two out of five cohorts into the single dose portion of the phase 1 trial within the next month new york, ny / accesswire / april 1, 2024 / protagenic therapeutics, inc. (nasdaq:ptix), a leader in biopharmaceutical innovation, today provided a corporate update and reported financial results for the fourth quarter and full year 2023. "in 2023, protagenic therapeutics achieved a significant milestone as we began enrolling patients for our neuropeptide drug candidate, pt00114," said dr...

Next clinical progress update expected in april 2024 new york, ny / accesswire / march 27, 2024 / protagenic therapeutics, inc. (nasdaq:ptix), a leader in biopharmaceutical innovation, advances its mission to develop cutting-edge treatments for stress-related neuropsychiatric disorders. the company has reached another milestone by completing three out of five cohorts of healthy volunteers with pt00114, its synthetic version of the stress-regulating peptide tcap, in a sad phase 1 clinical trial.

Call scheduled for monday, april 1st, 2024, at 4:30 pm et new york, ny / accesswire / march 25, 2024 / protagenic therapeutics, inc. (nasdaq:ptix), a biopharmaceutical innovator, announced that the company plans to hold its first investor earnings call to discuss the results contained in its fy 2023 form 10k, which it plans to file that day, and its outlook for fy 2024. the company plans to hold its earnings call, open to the public, at 4:30 pm et on monday, april 1st, to discuss the results of its q4 and fy 2023, which it plans to publish in its form 10k to be filed with the sec that day.

New york, ny / accesswire / march 21, 2024 / protagenic therapeutics, inc. (nasdaq:ptix), a biopharmaceutical innovator, regained compliance with nasdaq listing rule 5550(a)(2) as the closing bid price of shares of ptix has remained above $1.00 per share for ten consecutive trading days. this resolves the issue of potential delisting from nasdaq by may 19, 2024 that the company had been facing.

Protagenic Therapeutics, Inc. (PTIX) Q4 2023 Earnings Call Transcript

Call Scheduled for Monday, April 1st, 2024, at 4:30 pm ET NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, announced that the Company plans to hold its first investor earnings call to discuss the results contained in its FY 2023 Form 10K, which it plans to file that day, and its outlook for FY 2024. The Company plans to hold its earnings call, open to the public, at 4:30 pm ET on Monday, April 1st, to discuss the results of its Q4 and FY 2023, which it plans to publish in its Form 10K to be filed with the SEC that day.

NEW YORK, NY / ACCESSWIRE / October 13, 2023 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced its FY 2022 annual shareholder meeting will be held Wednesday, December 13, 2023, at 10:00 am EST, for shareholders of record as of this coming Monday, October 16th. Those who would like to attend the meeting virtually may do so by going to the website www.virtualshareholdermeeting.com/PTIX2023.

NEW YORK, NY / ACCESSWIRE / April 26, 2022 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing drug product candidates to treat stress-related neurologic disorders, today announced will be presenting at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference tomorrow, April 27, 2022.

The shares of Protagenic Therapeutics Inc (NASDAQ: PTIX) increased by over 10% pre-market. This is why it happened.

Upon reviewing Protagenic Therapeutics Inc's (NASDAQ: PTIX) Investigational New Drug (IND) application for its lead compound, PT00114, the FDA has currently rejected the Company's IND. The application sought approval to start a Phase 1/2a basket study designed to test PT00114 in healthy volunteers and patients with PTSD, anxiety, and depression.

NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced that it will host a key opinion leader (KOL) webinar focused on PT00114 for the regulation of stress in patients with Depression, PTSD, Anxiety and Addiction on Tuesday, July 13 at 10:00AM ET.

Penny stocks offer a lot of risk balanced by lots of reward. Here are 7 that could surge in price and which have reasonable catalysts behind them.

The stock price of Protagenic Therapeutics Inc (NASDAQ: PTIX) increased by over 25% pre-market. These are the details.

Looking for biotech penny stocks for your June watchlist? Here's 4 to watch The post Best Biotech Penny Stocks in June 2021?